We have located links that may give you full text access.
Gout drugs use and risk of cancer: A case-control study.
Joint, Bone, Spine : Revue du Rhumatisme 2018 December
OBJECTIVE: Firm conclusion about whether short and long-term gout medications use has an impact on cancer risk remain inconclusive. The aim of this study was to investigate the association between gout drugs use and risk of cancer.
METHODS: We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated by using conditional logistic regression.
RESULTS: We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95% CI: 0.994-1.020). There was a significant risk of leukemia (AOR: 1.34, 95% CI: 1.20-1.50), endometrial cancer (AOR: 1.33, 95% CI: 1.12-1.57), non-Hodgkin's (AOR: 1.24, 95% CI: 1.13-1.35), female breast cancer (AOR: 1.21, 95% CI: 1.13-1.29), cervical cancer (AOR: 1.21, 95% CI: 1.07-1.37). However, no association was observed in male group (AOR: 0.97, 95% CI: 0.95-0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95% CI: 1.08-1.13).
CONCLUSION: In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.
METHODS: We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated by using conditional logistic regression.
RESULTS: We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95% CI: 0.994-1.020). There was a significant risk of leukemia (AOR: 1.34, 95% CI: 1.20-1.50), endometrial cancer (AOR: 1.33, 95% CI: 1.12-1.57), non-Hodgkin's (AOR: 1.24, 95% CI: 1.13-1.35), female breast cancer (AOR: 1.21, 95% CI: 1.13-1.29), cervical cancer (AOR: 1.21, 95% CI: 1.07-1.37). However, no association was observed in male group (AOR: 0.97, 95% CI: 0.95-0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95% CI: 1.08-1.13).
CONCLUSION: In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app